In one paragraphArticle in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
4 authors.
Sjoukje LubbertsSjoukje Lubberts, MD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands; Flora E. van Leeuwen, PhD and Michael Schaapveld, PhD, Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Jourik A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.
Flora E van LeeuwenSjoukje Lubberts, MD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands; Flora E. van Leeuwen, PhD and Michael Schaapveld, PhD, Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Jourik A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.ORCID 0000-0002-5871-1484 Michael SchaapveldSjoukje Lubberts, MD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands; Flora E. van Leeuwen, PhD and Michael Schaapveld, PhD, Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Jourik A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.ORCID 0000-0003-4390-7182 Jourik A GietemaSjoukje Lubberts, MD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands; Flora E. van Leeuwen, PhD and Michael Schaapveld, PhD, Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Jourik A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.ORCID 0000-0003-0629-7354 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
What OpenQuestion holds
Textmetadata
Read underepoch 390